DOCSLIB.ORG

2021 EMPIRE PLAN FLEXIBLE FORMULARY DRUG LIST Administered by CVS Caremark®

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

April 2021 2021 EMPIRE PLAN FLEXIBLE FORMULARY DRUG LIST Administered by CVS Caremark® The Empire Plan Flexible Formulary is a guide within select therapeutic categories for enrollees and health care providers. Generics should be considered the first line of prescribing. If there is no generic available, there may be more than one brand-name drug to treat a condition. These preferred brand-name drugs are listed to help identify products that are clinically appropriate and cost-effective. This is not an all-inclusive list. This formulary includes a list of commonly prescribed covered drugs by therapeutic class, a Quick Reference Drug List with commonly prescribed covered drugs in alphabetic order, a listing of commonly prescribed non-preferred (Level 3) covered drugs and covered preferred drug alternatives, and a listing of excluded drugs along with covered alternatives. This list represents brand-name drugs in CAPS and generic drugs in lowercase italics. Generally generics are subject to a Level 1 copayment, or the lowest copayment; preferred brand drugs are subject to a Level 2 copayment, and non-preferred brand drugs are subject to a Level 3 copayment, or the highest copayment. Refer to your plan materials for specific information regarding copayment amounts. ENROLLEE HEALTH CARE PROVIDER Your benefit plan provides you with a prescription benefit program Your patient is covered under a prescription benefit plan administered administered by CVS Caremark. Ask your doctor to consider by CVS Caremark. As a way to help manage health care costs, prescribing, when medically appropriate, a preferred generic or a authorize generic substitution whenever possible. If you believe a preferred brand-name drug from this list. Take this list along when brand-name drug is necessary, consider prescribing a brand-name you or a covered family member sees a doctor. drug on this list. Please note: Please note: • You will be responsible for the full cost of non-formulary products • Generics should be considered the first line of prescribing. that are excluded from coverage unless a request for a • This drug list represents a summary of prescription coverage. medical exception is approved. New prescription drug products It is not all-inclusive and does not guarantee coverage. may be subject to exclusion upon release to the market. • The enrollee's prescription benefit plan may have a different • For specific information regarding your prescription benefit copay for specific products on the list. coverage and copay information, please visit • Unless specifically indicated, drug list products will include all https://www.empireplanrxprogram.com or dosage forms. call 1-877-7-NYSHIP (1-877-769-7447) and select option 4 • Log in to https://www.empireplanrxprogram.com to check for the Empire Plan Prescription Drug Program. coverage and copay information for a specific medicine. • Any brand-name drug for which a generic drug becomes available will be designated as a non-preferred drug. When a generic version is available, mandatory generic substitution will apply. In this case, use of a non-preferred product will result in the member paying the applicable non-preferred copayment plus the difference in cost between the brand-name drug and the generic, not to exceed the full retail cost of the drug (Ancillary Charge). ANALGESICS § NSAIDs, TOPICAL § OPIOID ANALGESICS hydromorphone ext-rel § NON-OPIOID ANALGESICS diclofenac sodium gel 1% buprenorphine transdermal QL/PA butalbital-acetaminophen- § NSAIDs (generic VOLTAREN GEL) (generic BUTRANS) methadone QL/PA caffeine diclofenac sodium QL/PA morphine QL/PA butalbital-aspirin-caffeine § COX-2 INHIBITORS diflunisal codeine-acetaminophen QL morphine ext-rel QL/PA etodolac celecoxib (generic fentanyl citrate (generic morphine suppository QL/PA VISCOSUPPLEMENTS ibuprofen CELEBREX) FENTORA) PA/QL oxycodone QL/PA DUROLANE meloxicam fentanyl transdermal QL/PA oxycodone-acetaminophen GELSYN-3 § GOUT nabumetone fentanyl transmucosal QL/PA HYALGAN naproxen (except naproxen CR or allopurinol lozenge PA/QL tramadol QL/PA SUPARTZ FX naproxen suspension) colchicine tablet (generic hydrocodone ext-rel (generic tramadol ext-rel QL/PA naproxen sodium COLCRYS) ZOHYDRO ER) QL/PA BELBUCA QL/PA ANTI-INFECTIVES oxaprozin febuxostat (generic ULORIC) HYSINGLA ER QL/PA hydrocodone-acetaminophen ANTIBACTERIALS sulindac probenecid (except hydrocodone-acetaminophen NUCYNTA QL/PA § CEPHALOSPORINS COLCRYS tablet 7.5-300 mg or hydrocodone- NUCYNTA ER QL/PA § NSAIDs, COMBINATIONS cefadroxil acetaminophen tablet 10-300 mg) OXYCONTIN QL/PA diclofenac sodium- cefdinir QL/PA SUBSYS PA/QL misoprostol cefixime (generic SUPRAX) XTAMPZA ER QL/PA hydromorphone QL/PA Your specific prescription benefit plan design may not cover certain products or categories, regardless of their appearance in this document. For specific information, visit https://www.empireplanrxprogram.com or call 1-877-7-NYSHIP (1-877-769-7447) and select option 4 for the Empire Plan Prescription Drug Program. 1 cefprozil emtricitabine-tenofovir nitazoxanide (generic MISCELLANEOUS § ANGIOTENSIN II cefuroxime axetil disoproxil fumarate ALINIA) ERIVEDGE SGM RECEPTOR ANTAGONIST / cephalexin (generic TRUVADA) nitrofurantoin LYNPARZA SGM CALCIUM CHANNEL SUPRAX SUSPENSION 500 BIKTARVY nitrofurantoin ext-rel RUBRACA SGM BLOCKER COMBINATIONS MG/5 ML, TABLET CIMDUO pentamidine (generic ZEJULA SGM amlodipine-olmesartan DESCOVY NEBUPENT) (generic AZOR) § ERYTHROMYCINS / DOVATO praziquantel (generic CARDIOVASCULAR MACROLIDES EVOTAZ BILTRICIDE) QL/PA § ANGIOTENSIN II § ACE INHIBITORS azithromycin GENVOYA sulfamethoxazole- RECEPTOR ANTAGONIST / clarithromycin ODEFSEY trimethoprim benazepril CALCIUM CHANNEL clarithromycin ext-rel SYMTUZA tinidazole captopril BLOCKER / DIURETIC erythromycin delayed-rel TRIUMEQ trimethoprim enalapril COMBINATIONS erythromycin ethylsuccinate TRUVADA vancomycin fosinopril olmesartan-amlodipine- erythromycin stearate ALINIA SUSPENSION lisinopril hydrochlorothiazide § ANTITUBERCULAR DIFICID EMVERM perindopril (generic TRIBENZOR) AGENTS SIVEXTRO quinapril § FLUOROQUINOLONES ethambutol XIFAXAN 550 MG ramipril § ANTIARRHYTHMICS ciprofloxacin isoniazid trandolapril amiodarone levofloxacin pyrazinamide ANTINEOPLASTIC disopyramide § ACE INHIBITOR / CALCIUM moxifloxacin rifampin AGENTS dofetilide (generic TIKOSYN) CHANNEL BLOCKER PRIFTIN SGM § PENICILLINS Generally, single-source brand COMBINATIONS TRECATOR drugs (products for which a flecainide amoxicillin generic is not available) and amlodipine-benazepril propafenone amoxicillin-clavulanate ANTIVIRALS generic drugs indicated for the trandolapril-verapamil ext-rel propafenone ext-rel treatment of cancer are amoxicillin-clavulanate ext-rel § CYTOMEGALOVIRUS (generic TARKA) formulary. sotalol ampicillin AGENTS § ACE INHIBITOR / MULTAQ dicloxacillin valganciclovir (generic HORMONAL penicillin VK DIURETIC COMBINATIONS ANTILIPEMICS VALCYTE) ANTINEOPLASTIC AGENTS benazepril- § ANTIANDROGENS § BILE ACID RESINS § TETRACYCLINES HEPATITIS AGENTS hydrochlorothiazide cholestyramine doxycycline hyclate abiraterone (generic captopril-hydrochlorothiazide Generally, single-source brand colesevelam (generic minocycline drugs (products for which a ZYTIGA) SGM enalapril-hydrochlorothiazide generic is not available) and WELCHOL) tetracycline ERLEADA SGM fosinopril-hydrochlorothiazide generic drugs indicated for the colestipol XTANDI SGM VIBRAMYCIN SYRUP treatment of Hepatitis B and lisinopril-hydrochlorothiazide Hepatitis C are formulary. YONSA SGM quinapril-hydrochlorothiazide § CHOLESTEROL § ANTIFUNGALS § LUTEINIZING HORMONE- ABSORPTION INHIBITORS clotrimazole troches § HEPATITIS B AGENTS § ADRENOLYTICS, RELEASING HORMONE CENTRAL ezetimibe (generic ZETIA) fluconazole entecavir tablet (LHRH) AGONISTS griseofulvin ultramicrosize lamivudine tablet clonidine § FIBRATES itraconazole PA ELIGARD SGM clonidine transdermal BARACLUDE SOLUTION fenofibrate (except fenofibrate tablet LUPRON DEPOT SGM nystatin EPIVIR-HBV SOLUTION guanfacine 120 mg) terbinafine tablet PA VEMLIDY § KINASE INHIBITORS fenofibric acid delayed-rel voriconazole § ALDOSTERONE gemfibrozil imatinib mesylate SGM RECEPTOR ANTAGONISTS NOXAFIL INJECTION, § HEPATITIS C AGENTS ALECENSA SGM SUSPENSION ribavirin SGM eplerenone § HMG-CoA REDUCTASE ALUNBRIG SGM EPCLUSA SGM spironolactone INHIBITORS / § ANTIMALARIALS BOSULIF SGM HARVONI SGM COMBINATIONS atovaquone-proguanil CABOMETYX SGM § ANGIOTENSIN II SOVALDI SGM atorvastatin chloroquine ◊ IBRANCE SGM RECEPTOR ANTAGONISTS / VOSEVI , SGM ezetimibe-simvastatin mefloquine ICLUSIG SGM DIURETIC COMBINATIONS (generic VYTORIN) pyrimethamine (generic § HERPES AGENTS IRESSA SGM candesartan fluvastatin DARAPRIM) KISQALI SGM candesartan- acyclovir lovastatin COARTEM KISQALI FEMARA CO- hydrochlorothiazide famciclovir pravastatin PACK SGM irbesartan valacyclovir rosuvastatin (generic ANTIRETROVIRAL AGENTS RYDAPT SGM irbesartan- CRESTOR) Generally, single-source brand § INFLUENZA AGENTS SPRYCEL SGM hydrochlorothiazide drugs (products for which a simvastatin generic is not available) and oseltamivir (generic TASIGNA SGM losartan generic drugs indicated for the TAMIFLU) QL/PA VERZENIO SGM losartan-hydrochlorothiazide § NIACINS treatment of HIV and its VITRAKVI SGM olmesartan (generic RELENZA QL/PA niacin ext-rel opportunistic infections are BENICAR) formulary. § MISCELLANEOUS MULTIPLE MYELOMA olmesartan- § OMEGA-3 FATTY ACIDS § ANTIRETROVIRAL albendazole (generic IMMUNOMODULATORS hydrochlorothiazide COMBINATIONS icosapent ethyl (generic ALBENZA) QL/PA
Recommended publications
  • Expert Review 2

    Expert Review 2

    2021 Expert Committee on Selection and Use of Essential Medicines Application review I.1 Albendazole, mebendazole and praziquantel for the indication of treatment of (item number) taeniid cestode cysts Does the application adequately ☒ Yes address the issue of the public health ☐ need for the medicine? No ☐ Not applicable Comments: The larval stages of three taeniid cestode parasites, Echinococcus granulosus, Echinococcus multilocularis and Taenia solium, produce cysts in humans that are of medical relevance. The diseases caused by these parasitic cysts are called cystic echinococcosis (CE), alveolar echinococcosis (AE), and cysticercosis (being neurocysticercosis (NCC) the most common form) respectively, and they are recognised by WHO as neglected tropical diseases. NCC is mainly a disease of poverty that predominantly affects rural populations in Africa, Asia and Latin America. Access to diagnostic and treatment, to better manage epilepsy and other NCC is a challenge for the people affected in these communities due to the availability and costs of specialised diagnostic and care. Stigma and social discrimination also mean that many people try to “hide” the disease. Briefly summarize the role of the The only real options for treatment of CE are albendazole (ALB) and Mebendazole proposed medicine(s) relative to other (MEB). ALB is the drug of choice as it has better bioavailability. ALB is also preferred to therapeutic agents currently included in MEB, because MEB requires a higher dose and a higher pill burden, for example, an the Model List, or available in the adult patient would require 8 tablets/day of MEB compared with 2 tablets/day ALB. market. ALB and praziquantel ( PZQ) are the only drugs used for the antiparasitic treatment of NCC.
  • ALBENDAZOLE (Extrapolation to All Ruminants)

    ALBENDAZOLE (Extrapolation to All Ruminants)

    European Medicines Agency Veterinary Medicines and Inspections EMEA/MRL/865/03-FINAL June 2004 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE ALBENDAZOLE (Extrapolation to all ruminants) SUMMARY REPORT (3) 1. Albendazole is a benzimidazole carbamate, used for the treatment of gastrointestinal infestations with roundworms, lungworms and tapeworms and adult flukes of Fasciola hepatica. Albendazole is currently entered into Annex I of Council Regulation (EEC) No. 2377/90 in accordance with the following table: Pharmacologically Marker residue Animal MRLs Target Other active substance(s) species tissues provisions Albendazole Sum of albendazole Bovine, 100 µg/kg Muscle sulphoxide, ovine 100 µg/kg Fat albendazole sulphone 1000 µg/kg Liver and albendazole 2- 500 µg/kg Kidney amino sulphone 100 µg/kg Milk expressed as albendazole 2. In reviewing the availability of endo- and ectoparasiticides for sheep and goats, albendazole was considered for extrapolation from bovine and ovine species to all ruminants. The considerations and criteria leading to the identification of albendazole are described in the Position Paper Regarding Availability of Veterinary Medicines – Extrapolation of MRLs (EMEA/CVMP/457/03-FINAL). 3. The scientific justification for this extrapolation was assessed in accordance with the Notes for Guidance on Risk Analysis Approach for Residues of Veterinary Medicinal Products in Food of Animal Origin (EMEA/CVMP/187/00-FINAL) and on the Establishment of Maximum Residue Limits for Minor Animal Species (EMEA/CVMP/153a/97-FINAL). 4. In setting the ADI in the original assessment of albendazole, the data summarised on the paragraphs below were considered. 5. The mode of action of albendazole is by binding strongly with the tubulin in the cells of nematodes.
  • Efficacy and Tolerability of Quinacrine Monotherapy and Albendazole Plus Chloroquine Combination Therapy in Nitroimidazole-Refractory Giardiasis: a Tropnet Study

    Efficacy and Tolerability of Quinacrine Monotherapy and Albendazole Plus Chloroquine Combination Therapy in Nitroimidazole-Refractory Giardiasis: a Tropnet Study

    Klinik für Infektiologie & Spitalhygiene Efficacy and tolerability of quinacrine monotherapy and albendazole plus chloroquine combination therapy in nitroimidazole-refractory giardiasis: a TropNet study Andreas Neumayr, Mirjam Schunk, Caroline Theunissen, Marjan Van Esbroeck, Matthieu Mechain, Manuel Jesús Soriano Pérez, Kristine Mørch, Peter Sothmann, Esther Künzli, Camilla Rothe, Emmanuel Bottieau Journal Club 01.03.21 Andreas Neumayr Background on giardia treatment: • 1st-line treatment: 5-nitroimidazoles: metronidazole (1957), tinidazole, ornidazole, secnidazole • cure rate of 5NIs in 1st-line treatment: ~90% • in the last decade, an increase of 5NI-refractory giardia cases has been observed in travel medicine clinics across Europe: Hospital for Tropical Diseases, London: 2008: 15% --> 2013: 40% 70% of 5NI-refractory cases imported from India • 2nd-line treatment: effectiveness of a 2nd round with a 5NI: ~17% alternative drugs: albendazole, mebendazole, nitazoxanide, quinacrine, furazolidone, chloroquine, paromomycin 2012 TropNet member survey: 53 centres use 39 different treatment regimens, consisting of 7 different drugs in mono- or combination-therapy in various dosages and durations JC 01.03.21 Nabarro LE et al. Clin Microbiol Infect. 2015;21:791-6. • by 2013, there were only 13 reports of 2nd-line therapy for giardiasis (8 case series, 5 individual case reports): n=110 Cure rates Albendazole 6/32 18.7% Paromomycin 5/17 29.4% Nitazoxanide 2/5 40.0% Albendazole + 5-NI 42/53 79.2% Quinacrine 19/21 90.5% Quinacrine + 5-NI 14/14 100% Quinacrine + Paromomycin 2/2 100% • 2013: TropNet "GiardiaREF" study kick-off: Study on efficacy and tolerability of two 2nd-line regimens in nitroimidazole-refractory giardiasis: Quinacrine JC 01.03.21 Meltzer E et al.
  • Folic Acid, Pyridoxine, and Cyanocobalamin Combination

    Folic Acid, Pyridoxine, and Cyanocobalamin Combination

    ORIGINAL INVESTIGATION Folic Acid, Pyridoxine, and Cyanocobalamin Combination Treatment and Age-Related Macular Degeneration in Women The Women’s Antioxidant and Folic Acid Cardiovascular Study William G. Christen, ScD; Robert J. Glynn, ScD; Emily Y. Chew, MD; Christine M. Albert, MD; JoAnn E. Manson, MD Background: Observational epidemiologic studies indi- and visually significant AMD, defined as confirmed in- cate a direct association between homocysteine concentra- cident AMD with visual acuity of 20/30 or worse attrib- tion in the blood and the risk of age-related macular degen- utable to this condition. eration (AMD), but randomized trial data to examine the effect of therapy to lower homocysteine levels in AMD are Results:Afteranaverageof7.3yearsoftreatmentandfollow- lacking. Our objective was to examine the incidence of AMD up, there were 55 cases of AMD in the combination treat- in a trial of combined folic acid, pyridoxine hydrochloride ment group and 82 in the placebo group (relative risk, 0.66; (vitamin B6), and cyanocobalamin (vitamin B12) therapy. 95% confidence interval, 0.47-0.93 [P=.02]). For visually significant AMD, there were 26 cases in the combination Methods: We conducted a randomized, double-blind, treatment group and 44 in the placebo group (relative risk, placebo-controlled trial including 5442 female health care 0.59; 95% confidence interval, 0.36-0.95 [P=.03]). professionals 40 years or older with preexisting cardio- vascular disease or 3 or more cardiovascular disease risk Conclusions: These randomized trial data from a large factors. A total of 5205 of these women did not have a cohort of women at high risk of cardiovascular disease diagnosis of AMD at baseline and were included in this indicate that daily supplementation with folic acid, pyri- analysis.
  • R Graphics Output

    R Graphics Output

    Dexamethasone sodium phosphate ( 0.339 ) Melengestrol acetate ( 0.282 ) 17beta−Trenbolone ( 0.252 ) 17alpha−Estradiol ( 0.24 ) 17alpha−Hydroxyprogesterone ( 0.238 ) Triamcinolone ( 0.233 ) Zearalenone ( 0.216 ) CP−634384 ( 0.21 ) 17alpha−Ethinylestradiol ( 0.203 ) Raloxifene hydrochloride ( 0.203 ) Volinanserin ( 0.2 ) Tiratricol ( 0.197 ) trans−Retinoic acid ( 0.192 ) Chlorpromazine hydrochloride ( 0.191 ) PharmaGSID_47315 ( 0.185 ) Apigenin ( 0.183 ) Diethylstilbestrol ( 0.178 ) 4−Dodecylphenol ( 0.161 ) 2,2',6,6'−Tetrachlorobisphenol A ( 0.156 ) o,p'−DDD ( 0.155 ) Progesterone ( 0.152 ) 4−Hydroxytamoxifen ( 0.151 ) SSR150106 ( 0.149 ) Equilin ( 0.3 ) 3,5,3'−Triiodothyronine ( 0.256 ) 17−Methyltestosterone ( 0.242 ) 17beta−Estradiol ( 0.24 ) 5alpha−Dihydrotestosterone ( 0.235 ) Mifepristone ( 0.218 ) Norethindrone ( 0.214 ) Spironolactone ( 0.204 ) Farglitazar ( 0.203 ) Testosterone propionate ( 0.202 ) meso−Hexestrol ( 0.199 ) Mestranol ( 0.196 ) Estriol ( 0.191 ) 2,2',4,4'−Tetrahydroxybenzophenone ( 0.185 ) 3,3,5,5−Tetraiodothyroacetic acid ( 0.183 ) Norgestrel ( 0.181 ) Cyproterone acetate ( 0.164 ) GSK232420A ( 0.161 ) N−Dodecanoyl−N−methylglycine ( 0.155 ) Pentachloroanisole ( 0.154 ) HPTE ( 0.151 ) Biochanin A ( 0.15 ) Dehydroepiandrosterone ( 0.149 ) PharmaCode_333941 ( 0.148 ) Prednisone ( 0.146 ) Nordihydroguaiaretic acid ( 0.145 ) p,p'−DDD ( 0.144 ) Diphenhydramine hydrochloride ( 0.142 ) Forskolin ( 0.141 ) Perfluorooctanoic acid ( 0.14 ) Oleyl sarcosine ( 0.139 ) Cyclohexylphenylketone ( 0.138 ) Pirinixic acid ( 0.137 )
  • Study Assessing Prices, Availability and Affordability of Children's

    Study Assessing Prices, Availability and Affordability of Children's

    Study assessing prices, availability and affordability of children’s medicine in Chhattisgarh, India Part of the Better Medicine for Children project Authors Dr Antony KR Virendra Jain Puni Kokho Dr Kamlesh Jain The salient findings and views expressed in this report are solely those of the authors. Please direct correspondence to the authors: ([email protected], [email protected] [email protected], [email protected]). This publication does not necessarily represent the decisions or policies of the World Health Organization. ii Contents Acknowledgements ........................................................................................... v Abbreviations ................................................................................................... vi Executive summary ......................................................................................... vii Medicine availability .............................................................................................vii Medicine costs ................................................................................................... viii Affordability of standard treatment regimens ........................................................... ix Price components survey ...................................................................................... ix Conclusion .......................................................................................................... x 1. Introduction .................................................................................................
  • Guidelines on Food Fortification with Micronutrients

    Guidelines on Food Fortification with Micronutrients

    GUIDELINES ON FOOD FORTIFICATION FORTIFICATION FOOD ON GUIDELINES Interest in micronutrient malnutrition has increased greatly over the last few MICRONUTRIENTS WITH years. One of the main reasons is the realization that micronutrient malnutrition contributes substantially to the global burden of disease. Furthermore, although micronutrient malnutrition is more frequent and severe in the developing world and among disadvantaged populations, it also represents a public health problem in some industrialized countries. Measures to correct micronutrient deficiencies aim at ensuring consumption of a balanced diet that is adequate in every nutrient. Unfortunately, this is far from being achieved everywhere since it requires universal access to adequate food and appropriate dietary habits. Food fortification has the dual advantage of being able to deliver nutrients to large segments of the population without requiring radical changes in food consumption patterns. Drawing on several recent high quality publications and programme experience on the subject, information on food fortification has been critically analysed and then translated into scientifically sound guidelines for application in the field. The main purpose of these guidelines is to assist countries in the design and implementation of appropriate food fortification programmes. They are intended to be a resource for governments and agencies that are currently implementing or considering food fortification, and a source of information for scientists, technologists and the food industry. The guidelines are written from a nutrition and public health perspective, to provide practical guidance on how food fortification should be implemented, monitored and evaluated. They are primarily intended for nutrition-related public health programme managers, but should also be useful to all those working to control micronutrient malnutrition, including the food industry.
  • Valbazen ® (Albendazole)

    Valbazen ® (Albendazole)

    ® (albendazole oral suspension) Broad-Spectrum Dewormer Oral Suspension for Use in Cattle, Sheep, and Goats for removal and control of liver flukes, tapeworms, stomach worms (including 4th stage inhibited larvae of Ostertagia ostertagi), intestinal worms, and lungworms in cattle and sheep and for the treatment of adult liver flukes in nonlactating goats Active Ingredient Albendazole ............................. 11.36% (equivalent to 113.6 mg/mL) 1 L/33.8 fl oz (1 qt 1.8 fl oz) Approved by FDA under NADA # 110-048 40029175 ® (albendazole oral suspension) Broad-Spectrum Dewormer Oral Suspension for Use in Cattle, Sheep, and Goats for removal and control of liver Indications: flukes, tapeworms, stomach worms (including 4th stage inhibited larvae of Ostertagia Cattle and sheep: Valbazen is a broad-spectrum anthelmintic effective in the removal ostertagi), intestinal worms, and lungworms in cattle and sheep and for the treatment and control of liver flukes, tapeworms, stomach worms (including 4th stage inhibited of adult liver flukes in nonlactating goats larvae of Ostertagia ostertagi ), intestinal worms, and lungworms as indicated below. Active Ingredient: Goats: For the treatment of adult liver flukes in nonlactating goats. Albendazole .......................................................... 11.36% (Equivalent to 113.6 mg/mL) Parasite Cattle Sheep Goats Adult Liver Flukes Fasciola hepatica Fasciola hepatica, Fascioloides magna Fasciola hepatica Heads and Segments Moniezia benedeni, M. expansa Common Tapeworm (Moniezia expansa), Fringed Tapeworm of Tapeworms (Thysanosoma actinioides) Adult and 4th Stage Brown Stomach Worm, including 4th stage Brown Stomach Worm (Ostertagia circumcincta, Marshallagia Larvae of Stomach inhibited larvae (Ostertagia ostertagi), marshalli), Barber Pole Worm (Haemonchus contortus), Small Worms Barber Pole Worm (Haemonchus Stomach Worm (Trichostrongylus axei) contortus, H.
  • These Highlights Do Not Include All the Information Needed to Use M.V.I. Pediatric® Safely and Effectively

    These Highlights Do Not Include All the Information Needed to Use M.V.I. Pediatric® Safely and Effectively

    M.V.I. PEDIATRIC- ascorbic acid, retinol, ergocalciferol, thiamine hydrochloride, riboflavin 5- phosphate sodium, pyridoxine hydrochloride, niacinamide, dexpanthenol, .alpha.-tocopherol acetate, dl-, biotin, folic acid, cyanocobalamin, and phytonadione injection, powder, lyophilized, for solution Hospira, Inc. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use M.V.I. Pediatric® safely and effectively. See full prescribing information for M.V.I. Pediatric. M.V.I. Pediatric (multiple vitamins for injection), for intravenous use Initial U.S. Approval: 1983 RECENT MAJOR CHANGES Dosage And Administration, Dosage Information (2.2) 2/2019 INDICATIONS AND USAGE M.V.I. Pediatric is a combination of vitamins indicated for the prevention of vitamin deficiency in pediatric patients up to 11 years of age receiving parenteral nutrition (1) DOSAGE AND ADMINISTRATION M.V.I. Pediatric is a combination product that contains the following vitamins: ascorbic acid, vitamin A, vitamin D, thiamine, riboflavin, pyridoxine, niacinamide, dexpanthenol, vitamin E, vitamin K, folic acid, biotin, and vitamin B12 (2.1) Supplied as a single-dose vial of lyophilized powder for reconstitution intended for administration by intravenous infusion after dilution. (2.1) Recommended daily dosage is based on patient's actual weight (2.2) Less than 1 kg: The daily dose is 1.5 mL 1 kg to 3 kg: The daily dose is 3.25 mL 3 kg or more: The daily dose is 5 mL One daily dose of the reconstituted solution (1.5 mL, 3.25 mL or 5 mL) is then added directly to the intravenous fluid (2.2,2.3) See Full Prescribing Information for reconstitution instructions (2.3) Monitor blood vitamin concentrations (2.4) See Full Prescribing Information for drug incompatibilities (2.5) DOSAGE FORMS AND STRENGTHS M.V.I.
  • Becosules Junior

    Becosules Junior

    For the use of a Registered Medical Practitioner or a Hospital or a Laboratory only Multivitamin with Vitamin A and Vitamin D3 Liquid BECOSULES JUNIOR 1. NAME OF THE MEDICINAL PRODUCT BECOSULES JUNIOR 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each 5 ml (1 teaspoonful) contains: Vitamin A Concentrate Oil I.P. (as Palmitate) 2500 IU Cholecalciferol I.P. 200 IU Thiamine Hydrochloride I.P. 2 mg Riboflavin Sodium Phosphate I.P. 2.54 mg Pyridoxine Hydrochloride I.P. 1 mg Niacinamide I.P. 20 mg D-Panthenol I.P. 5 mg Ascorbic Acid I.P. 50 mg For Pediatric Use For a full list of excipients, see section 6.1. 3. PHARMACOLOGICAL FORM Liquid Trademark Owner: Pfizer Products Inc. USA; Licensed User: Pfizer Limited, India BECOSULES JUNIOR Page 1 of 9 LPDBECJR122017 4. CLINICAL PARTICULARS 4.1 Indications Becosules Junior is indicated in the treatment of patients with deficiencies of, or increased requirement for vitamins A, B complex, C and D. Such patients and conditions include: • Decreased intake because of restricted or unbalanced diet as in anorexia, diabetes mellitus and obesity, and insufficient sunlight exposure.1 • Reduced availability during treatment with antimicrobials which alter normal intestinal flora, and anticonvulsants and glucocorticoids which alter vitamin D metabolism1, in prolonged diarrhea and in chronic gastrointestinal disorders. • Increased requirements due to increased metabolic rate as in fever and tissue wasting, e.g. febrile illness, acute or chronic infections, surgery, burns and fractures. • Stomatitis, glossitis, cheilosis, paraesthesias, neuralgia and dermatitis. 4.2 Posology and Method of Administration For children from 1-3 years - 1.25 ml, 4-9 years - 2.5 ml; and 10-13 years - 5 ml or as directed by physician.
  • B-COMPLEX FORTE with VITAMIN C CAPSULES BECOSULES Capsules

    B-COMPLEX FORTE with VITAMIN C CAPSULES BECOSULES Capsules

    For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory. B-COMPLEX FORTE WITH VITAMIN C CAPSULES BECOSULES Capsules 1. NAME OF THE MEDICINAL PRODUCT BECOSULES 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains: Thiamine Mononitrate I.P. 10 mg Riboflavin I.P. 10 mg Pyridoxine Hydrochloride I.P. 3 mg Vitamin B12 I.P. ( as STABLETS 1:100) 15 mcg Niacinamide I.P. 100 mg Calcium Pantothenate I.P. 50 mg Folic Acid I.P. 1.5 mg Biotin U.S.P. 100 mcg Ascorbic Acid I.P. (as coated) 150 mg Appropriate overages added For Therapeutic Use For a full list of excipients, see section 6.1. All strengths/presentations mentioned in this document might not be available in the market. 3. PHARMACOLOGICAL FORM Capsules 4. CLINICAL PARTICULARS 4.1 Therapeutic Indications Trademark Proprietor: Pfizer Products Inc. USA Licensed User: Pfizer Limited, India BECOSULES Capsules Page 1 of 7 LPDBCC092017 PfLEET Number: 2017-0033507 Becosules capsules are indicated in the treatment of patients with deficiencies of, or increased requirement for, vitamin B-complex, and vitamin C. Such patients and conditions include: Decreased intake because of restricted or unbalanced diet as in anorexia, diabetes mellitus, obesity and alcoholism. Reduced availability during treatment with antimicrobials which alter normal intestinal flora, in prolonged diarrhea and in chronic gastro-intestinal disorders. Increased requirements due to increased metabolic rate as in fever and tissue wasting, e.g. febrile illness, acute or chronic infections, surgery, burns and fractures. Stomatitis, glossitis, cheilosis, paraesthesias, neuralgia and dermatitis. Micronutrient deficiencies during pregnancy or lactation.
  • Albendazole: a Review of Anthelmintic Efficacy and Safety in Humans

    Albendazole: a Review of Anthelmintic Efficacy and Safety in Humans

    S113 Albendazole: a review of anthelmintic efficacy and safety in humans J.HORTON* Therapeutics (Tropical Medicine), SmithKline Beecham International, Brentford, Middlesex, United Kingdom TW8 9BD This comprehensive review briefly describes the history and pharmacology of albendazole as an anthelminthic drug and presents detailed summaries of the efficacy and safety of albendazole’s use as an anthelminthic in humans. Cure rates and % egg reduction rates are presented from studies published through March 1998 both for the recommended single dose of 400 mg for hookworm (separately for Necator americanus and Ancylostoma duodenale when possible), Ascaris lumbricoides, Trichuris trichiura, and Enterobius vermicularis and, in separate tables, for doses other than a single dose of 400 mg. Overall cure rates are also presented separately for studies involving only children 2–15 years. Similar tables are also provided for the recommended dose of 400 mg per day for 3 days in Strongyloides stercoralis, Taenia spp. and Hymenolepis nana infections and separately for other dose regimens. The remarkable safety record involving more than several hundred million patient exposures over a 20 year period is also documented, both with data on adverse experiences occurring in clinical trials and with those in the published literature and\or spontaneously reported to the company. The incidence of side effects reported in the published literature is very low, with only gastrointestinal side effects occurring with an overall frequency of just "1%. Albendazole’s unique broad-spectrum activity is exemplified in the overall cure rates calculated from studies employing the recommended doses for hookworm (78% in 68 studies: 92% for A. duodenale in 23 studies and 75% for N.